Sachin Jain
Stock Analyst at Bank of America Securities
(3.05)
# 2,587
Out of 4,575 analysts
266
Total ratings
53.6%
Success rate
2.4%
Average return
Main Sectors:
Stocks Rated by Sachin Jain
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPA: SAN Sanofi | Maintained: Hold | €92.00 | €76.03 | +21.00% | 22 | Jul 24, 2026 | |
| NVS Novartis AG | Maintained: Buy | n/a | $155.01 | - | 4 | Jul 21, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 140.00 | CHF 126.90 | +10.32% | 27 | Jul 21, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,500p | 12,670p | +30.23% | 81 | Jul 9, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 2,350p | 1,920p | +22.43% | 14 | Jun 30, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 340.00 → kr 350.00 | kr 320.60 | +9.17% | 27 | Feb 5, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €30.00 → €35.00 | €46.06 | -24.01% | 9 | Dec 2, 2025 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 1,950 → kr 2,250 | kr 1,877 | +19.84% | 23 | Nov 25, 2025 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | €10.60 | €9.66 | +9.78% | 1 | Nov 25, 2025 | |
| GSK GSK plc | Reiterated: Sell | $48 → $23 | $51.35 | -55.90% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $138 → $57 | $48.77 | +16.96% | 37 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | CHF 275.00 → CHF 340.00 | CHF 355.10 | n/a | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €110.00 → €205.00 | €139.15 | n/a | 3 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $49 | $28.87 | n/a | 4 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $24 | $28.42 | n/a | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $195 | $54.07 | n/a | 1 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $24.54 | n/a | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $146.99 | n/a | 1 | May 2, 2016 |
Sanofi
Jul 24, 2026
Maintained: Hold
Price Target: €92.00
Current: €76.03
Upside: +21.00%
Novartis AG
Jul 21, 2026
Maintained: Buy
Price Target: n/a
Current: $155.01
Upside: -
Novartis AG
Jul 21, 2026
Reiterated: Buy
Price Target: CHF 140.00
Current: CHF 126.90
Upside: +10.32%
AstraZeneca PLC
Jul 9, 2026
Reiterated: Buy
Price Target: 16,500p
Current: 12,670p
Upside: +30.23%
GSK plc
Jun 30, 2026
Reiterated: Hold
Price Target: 2,350p
Current: 1,920p
Upside: +22.43%
Novo Nordisk A/S
Feb 5, 2026
Maintained: Hold
Price Target: kr 340.00 → kr 350.00
Current: kr 320.60
Upside: +9.17%
Bayer Aktiengesellschaft
Dec 2, 2025
Maintained: Buy
Price Target: €30.00 → €35.00
Current: €46.06
Upside: -24.01%
Genmab A/S
Nov 25, 2025
Maintained: Buy
Price Target: kr 1,950 → kr 2,250
Current: kr 1,877
Upside: +19.84%
Grifols, S.A.
Nov 25, 2025
Maintained: Buy
Price Target: €10.60
Current: €9.66
Upside: +9.78%
GSK plc
Oct 29, 2025
Reiterated: Sell
Price Target: $48 → $23
Current: $51.35
Upside: -55.90%
Oct 9, 2025
Maintained: Hold
Price Target: $138 → $57
Current: $48.77
Upside: +16.96%
Sep 13, 2024
Upgraded: Buy
Price Target: CHF 275.00 → CHF 340.00
Current: CHF 355.10
Upside: n/a
Jun 12, 2023
Maintained: Buy
Price Target: €110.00 → €205.00
Current: €139.15
Upside: n/a
May 11, 2023
Reiterated: Buy
Price Target: $48 → $49
Current: $28.87
Upside: n/a
Feb 2, 2023
Maintained: Hold
Price Target: $24
Current: $28.42
Upside: n/a
Jan 17, 2023
Maintained: Hold
Price Target: $195
Current: $54.07
Upside: n/a
Nov 1, 2022
Maintained: Buy
Price Target: $60
Current: $24.54
Upside: n/a
May 2, 2016
Maintained: Buy
Price Target: n/a
Current: $146.99
Upside: n/a